Desazadesmethyldesferrithiocin analogues as orally effective iron chelators

被引:70
作者
Bergeron, RJ [1 ]
Wiegand, J [1 ]
Weimar, WR [1 ]
Vinson, JRT [1 ]
Bussenius, J [1 ]
Yao, GW [1 ]
McManis, JS [1 ]
机构
[1] Univ Florida, Dept Med Chem, Gainesville, FL 32610 USA
关键词
D O I
10.1021/jm980340j
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Further structure-activity studies of desferrithiocin analogues are carried out. (S)-desazadesmethyldesferrithiocin, 2-(2-hydroxyphenyl)-Delta(2)-thiazoline-4(S)-carboxylic acid, serves as the principal framework in the current paper. Desazadesmethyldesferrithiocin can be structurally altered with facility, and data are already available on its iron-clearing properties and toxicity parameters. Four different kinds of structural modifications of this framework are undertaken: introduction of hydroxy, carboxy, or methoxy groups on the aromatic ring; alteration of the thiazoline ring; increasing the distance between the ligand donor atoms; and benz-fusion of the aromatic rings. The structural modifications described are shown to have a tremendous imp act on both the iron clearance and toxicity profiles of the desazadesmethyldesferrithiocin molecule. All of the compounds are assessed in a bile-duct-cannulated rodent model to determine iron clearance efficiency. Ligands which demonstrate an efficiency of greater than 2% are carried forward to the iron-overloaded primate for iron-clearing measurements. Ligands with efficiencies greater than 3% in the primate are then evaluated in a formal toxicity study in rodents. On the basis of the results of the present work, 2-(2,4-dihydroxyphenyl)-Delta(2)-thiazoline-4(S)-carboxylic acid is a promising candidate for clinical evaluation.
引用
收藏
页码:95 / 108
页数:14
相关论文
共 51 条
[1]   METAL-COMPLEX FORMATION OF A NEW SIDEROPHORE DESFERRITHIOCIN AND OF 3 RELATED LIGANDS [J].
ANDEREGG, G ;
RABER, M .
JOURNAL OF THE CHEMICAL SOCIETY-CHEMICAL COMMUNICATIONS, 1990, (17) :1194-1196
[2]  
BERGERON RJ, 1990, ANN NY ACAD SCI, V612, P378
[3]  
BERGERON RJ, 1993, BLOOD, V81, P2166
[4]   THE DESFERRITHIOCIN PHARMACOPHORE [J].
BERGERON, RJ ;
LIU, CZ ;
MCMANIS, JS ;
XIA, MXB ;
ALGEE, SE ;
WIEGAND, J .
JOURNAL OF MEDICINAL CHEMISTRY, 1994, 37 (10) :1411-1417
[5]  
BERGERON RJ, 1992, BLOOD, V79, P1882
[6]   HBED: A potential alternative to deferoxamine for iron-chelating therapy [J].
Bergeron, RJ ;
Wiegand, J ;
Brittenham, GM .
BLOOD, 1998, 91 (04) :1446-1452
[7]   AN EFFICIENT TOTAL SYNTHESIS OF AGROBACTIN AND ITS GALLIUM(III) CHELATE [J].
BERGERON, RJ ;
MCMANIS, JS ;
DIONIS, JB ;
GARLICH, JR .
JOURNAL OF ORGANIC CHEMISTRY, 1985, 50 (15) :2780-2782
[8]   SHORT SYNTHESIS OF PARABACTIN [J].
BERGERON, RJ ;
KLINE, SJ .
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 1982, 104 (16) :4489-4492
[9]   SYNTHESIS AND SOLUTION STRUCTURE OF MICROBIAL SIDEROPHORES [J].
BERGERON, RJ .
CHEMICAL REVIEWS, 1984, 84 (06) :587-602
[10]   Synthesis and biological evaluation of naphthyldesferrithiocin iron chelators [J].
Bergeron, RJ ;
Wiegand, J ;
Wollenweber, M ;
McManis, JS ;
Algee, SE ;
RatliffThompson, K .
JOURNAL OF MEDICINAL CHEMISTRY, 1996, 39 (08) :1575-1581